21 Apr 2021 |
Johnson & Johnson COVID-19 Vaccine Roll-out to Resume in Europe Following European Medicines Agency (EMA) Review
|
20 Apr 2021 |
Vertex Pharmaceuticals and CRISPR Therapeutics Amend Collaboration for Development, Manufacturing and Commercialization of CTX001™ in Sickle Cell Disease and Beta Thalassemia
|
20 Apr 2021 |
Steba Biotech Treats First Patient in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract Urothelial Cancer
|
15 Apr 2021 |
New protein degradation centre to lead drug discovery revolution
|
14 Apr 2021 |
BERG Announces Oncology Pipeline Advancements And Biomarker Developments For Clinical Decision Support In Breast Cancer At AACR
|
09 Apr 2021 |
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas
|
06 Apr 2021 |
Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
|
05 Apr 2021 |
Cidara Therapeutics Announces Agreement with Janssen to Develop and Commercialize AVCs for the Prevention and Treatment of Influenza
|
02 Apr 2021 |
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
|
02 Apr 2021 |
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
|
02 Apr 2021 |
Eloxx Pharmaceuticals Acquires Zikani Therapeutics
|
30 Mar 2021 |
Leiden University Medical Center and Ixaka enter collaboration to strengthen knowledge of cell therapy candidate REX-001
|
30 Mar 2021 |
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
|
30 Mar 2021 |
BridGene Biosciences Announces Research Collaboration with Takeda to Discover Small Molecule Drugs for "Undruggable" Targets
|
23 Mar 2021 |
PhoreMost closes £33M ($46M) Series B financing
|
22 Mar 2021 |
SemaThera Enters into a Research Collaboration and Exclusive License Agreement with Roche
|
18 Mar 2021 |
Boston Pharmaceuticals Enters into Unique Multi-Year Out-License and Option Agreement with GSK for the Advancement of Multiple Pre-Phase 2 Programs
|
17 Mar 2021 |
Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets
|
17 Mar 2021 |
Amathus Therapeutics Signs Strategic Collaboration With Merck to Develop Treatments for Neurodegenerative Diseases
|
17 Mar 2021 |
Seekyo raises over €650,000 from business angels and Bpifrance
|
17 Mar 2021 |
DZNE and Eisai enter into research collaboration agreement aiming for novel drug discovery for neurodegenerative disorders
|
16 Mar 2021 |
GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.
|
16 Mar 2021 |
Perception Neuroscience And Otsuka Pharmaceutical Announce Collaboration On Development Of PCN-101 (R-ketamine) In Japan For Treatment-of Depressive Disorders
|
16 Mar 2021 |
Boehringer Ingelheim and The Lieber Institute for Brain Development to Collaborate to Develop Centrally Acting COMT Inhibitors for Treatment of Neuropsychiatric Disorders
|
15 Mar 2021 |
Genevant Sciences Announces Global Collaboration and License Agreement with Takeda to Develop Novel Nucleic Acid Therapeutics for Liver Fibrosis
|